Compare Illumina, Inc. (ILMN) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Lemonade Inc — how do they compare? Illumina, Inc. trades at $270.94 (market cap $39.95B), while Lemonade Inc trades at $46.61 (market cap $3.63B). The key difference: Illumina, Inc. is far larger — about 11× Lemonade Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Lemonade Inc for 27 Days on average.
| ILMN | LMND | |
|---|---|---|
Market Cap | $39.95B | $3.63B |
Volume | 3,169,503 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $293.69 | $96.57 |
52-Week Low | $91.00 | $43.91 |
Typical Hold Time | 83 Days | 27 Days |
Enterprise Value | $41.31B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Lemonade (LMND) trades at $46.83, up 1.14% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth is accelerating, reaching $738M in 2025, with a narrowing net loss margin from -116% in 2022 to -22.4% in 2025. The company is expanding geographically and product-wise, supported by AI-driven efficiency, targeting EBITDA profitability by late 2026.
The outlook is mixed: strong growth and path to profitability present opportunity, but persistent losses, high valuation multiples, and bearish technicals pose risks. The consensus price target of $67 implies significant upside if execution continues, but investor sentiment remains divided given the stock's high volatility and unprofitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
